TR199801432A2 - Rasemizasyona karsi stabilize edilmis farmakolojik silansetron karisimlari. - Google Patents

Rasemizasyona karsi stabilize edilmis farmakolojik silansetron karisimlari.

Info

Publication number
TR199801432A2
TR199801432A2 TR1998/01432A TR9801432A TR199801432A2 TR 199801432 A2 TR199801432 A2 TR 199801432A2 TR 1998/01432 A TR1998/01432 A TR 1998/01432A TR 9801432 A TR9801432 A TR 9801432A TR 199801432 A2 TR199801432 A2 TR 199801432A2
Authority
TR
Turkey
Prior art keywords
silansetron
minus
salts
pharmacological
cilansetron
Prior art date
Application number
TR1998/01432A
Other languages
English (en)
Other versions
TR199801432A3 (tr
Inventor
Bonnacker Ingo
K�Hn Hartmut
Kristen Gerhard
Reichel Christine
Original Assignee
Solvay Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals Gmbh filed Critical Solvay Pharmaceuticals Gmbh
Publication of TR199801432A2 publication Critical patent/TR199801432A2/tr
Publication of TR199801432A3 publication Critical patent/TR199801432A3/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Silansetron veya onun asit katki tuzlari, etken madde içeren kati veya sivi farmakolojik karisim olarak tanimlanmaktadir, ki bunlar rasemizasyona karsi silansetronun strabilizasyonu için, 2 ila 12'ye kadar karbon atomlu ve 1,1 ile 4,8 arasinda bir birinci pKs degerli, belirtilen çok bazli organik asitlerin eksi tuzlari ve 1,5 ile 7,5 arasinda hazir bir birinci pKs - degerli çok bazli maden asitlerin eksi tuzlari ile bir veya çok bazli organik asitlerden seçilmis fizyolojik olarak uyumlu suda çözünür eksi bir katki maddesinin yeter miktarini içermektedir. Bunun disinda,rasemizasyona karsi silansetronun stabilizasyonu için eksi katki maddelerinin farmakolojik karisimlarda kullanimi tarif edilmektedir.
TR1998/01432A 1997-08-01 1998-07-23 Rasemizasyona karsi stabilize edilmis farmakolojik silansetron karisimlari. TR199801432A3 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19733271 1997-08-01
DE19813661A DE19813661A1 (de) 1997-08-01 1998-03-27 Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron

Publications (2)

Publication Number Publication Date
TR199801432A2 true TR199801432A2 (tr) 1999-02-22
TR199801432A3 TR199801432A3 (tr) 1999-02-22

Family

ID=7837672

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/01432A TR199801432A3 (tr) 1997-08-01 1998-07-23 Rasemizasyona karsi stabilize edilmis farmakolojik silansetron karisimlari.

Country Status (29)

Country Link
US (1) US5977127A (tr)
EP (1) EP0895782B1 (tr)
JP (1) JP4324260B2 (tr)
KR (1) KR100515201B1 (tr)
CN (1) CN1117565C (tr)
AR (1) AR010178A1 (tr)
AT (1) ATE283706T1 (tr)
AU (1) AU743043B2 (tr)
BR (1) BR9803730A (tr)
CA (1) CA2244389C (tr)
CZ (1) CZ295072B6 (tr)
DE (2) DE19813661A1 (tr)
DK (1) DK0895782T3 (tr)
DZ (1) DZ2560A1 (tr)
ES (1) ES2234051T3 (tr)
HK (1) HK1017611A1 (tr)
HU (1) HUP9801712A3 (tr)
ID (1) ID20685A (tr)
IL (1) IL125403A (tr)
NO (1) NO323229B1 (tr)
NZ (1) NZ331083A (tr)
PL (1) PL191767B1 (tr)
PT (1) PT895782E (tr)
RU (1) RU2199318C2 (tr)
SK (1) SK284916B6 (tr)
TR (1) TR199801432A3 (tr)
TW (1) TW509570B (tr)
UA (1) UA62924C2 (tr)
ZA (1) ZA986715B (tr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452545B2 (en) * 2001-11-13 2008-11-18 Yu Ruey J Oligosaccharide aldonic acids and their topical use
CA2439097C (en) * 2001-03-26 2010-10-12 Novartis Ag Pharmaceutical compositions
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
EP1558081A4 (en) * 2003-01-13 2006-06-14 Dynogen Pharmaceuticals Inc METHOD OF TREATING FUNCTIONAL INTESTINAL DISORDERS
MXPA05007379A (es) * 2003-01-13 2006-02-10 Dynogen Pharmaceuticals Inc Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos.
DE602004007225T2 (de) * 2003-04-04 2008-03-06 Dynogen Pharmaceuticals Inc., Waltham Methode zur behandlung von erkrankungen der unteren harnwege
US7820690B2 (en) * 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
RU2011108420A (ru) 2008-08-14 2012-09-20 Киорин Фармасьютикал Ко., Лтд. (Jp) Стабилизированный фармацевтический состав
JPWO2021100728A1 (tr) 2019-11-20 2021-05-27

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0297651B1 (en) * 1987-06-29 1993-11-03 Duphar International Research B.V Anellated indole derivatives
DE4238553A1 (de) * 1992-11-14 1994-05-19 Kali Chemie Pharma Gmbh Neue Imidazol-1-yl-Verbindungen enthaltende Arzneimittel
AU702594B2 (en) * 1995-10-13 1999-02-25 Duphar International Research B.V. Process for the preparation of enantiomerically pure imidazolyl compounds

Also Published As

Publication number Publication date
SK100998A3 (en) 1999-02-11
SK284916B6 (sk) 2006-02-02
KR19990023194A (ko) 1999-03-25
NZ331083A (en) 2000-01-28
PL327786A1 (en) 1999-02-15
AU7863098A (en) 1999-02-11
ES2234051T3 (es) 2005-06-16
DE59812317D1 (de) 2005-01-05
PL191767B1 (pl) 2006-06-30
NO983540L (no) 1999-02-02
ID20685A (id) 1999-02-18
RU2199318C2 (ru) 2003-02-27
EP0895782A3 (de) 2001-01-31
CN1117565C (zh) 2003-08-13
AR010178A1 (es) 2000-05-17
NO323229B1 (no) 2007-02-05
ATE283706T1 (de) 2004-12-15
BR9803730A (pt) 2000-03-28
CZ295072B6 (cs) 2005-05-18
TW509570B (en) 2002-11-11
JP4324260B2 (ja) 2009-09-02
TR199801432A3 (tr) 1999-02-22
HUP9801712A3 (en) 2001-08-28
DK0895782T3 (da) 2005-01-03
CZ236798A3 (cs) 1999-02-17
HUP9801712A2 (hu) 1999-04-28
HU9801712D0 (en) 1998-09-28
JPH1192369A (ja) 1999-04-06
NO983540D0 (no) 1998-07-31
ZA986715B (en) 1999-02-04
EP0895782A2 (de) 1999-02-10
DZ2560A1 (fr) 2003-02-15
KR100515201B1 (ko) 2005-12-09
CN1207292A (zh) 1999-02-10
CA2244389A1 (en) 1999-02-01
IL125403A0 (en) 1999-03-12
DE19813661A1 (de) 1999-02-04
IL125403A (en) 2001-11-25
HK1017611A1 (en) 1999-11-26
AU743043B2 (en) 2002-01-17
UA62924C2 (en) 2004-01-15
US5977127A (en) 1999-11-02
CA2244389C (en) 2008-01-15
EP0895782B1 (de) 2004-12-01
PT895782E (pt) 2005-02-28

Similar Documents

Publication Publication Date Title
TR199801432A2 (tr) Rasemizasyona karsi stabilize edilmis farmakolojik silansetron karisimlari.
PE55498A1 (es) Compuestos de triarilo
BR9806296B1 (pt) compostos de ácido sulfìnico, mistura, composição e uso dos mesmos.
GB2362163A (en) Diesel fuel composition
DE3770095D1 (de) Chinazolindione und pyridopyrimidindione.
DE59708148D1 (de) Kosmetisches präparat mit peptidzusatz
SV1998000008A (es) Inhibisores de sulfamida-metaloproteasa. ref. ran 4070\114
HUP0001383A1 (hu) N-(Aril/heteroaril)-aminosav-származékok, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
TR199802455T2 (tr) Yakit katki maddeleri.
MY129957A (en) Aqueous liquid agricultural composition
DE69720269T2 (de) Gelierungsstabiele polyhalogenphosphazenverbindungen
IE41648L (en) BENZ [de] ISOQUINOLINE DERIVATIVES
ES2000456A6 (es) Procedimiento para preparar deirvados de acido eicosatriinoico-5,8,11 y utilizacion de estos en composiciones farmaceuticas y cosmeticas.
MX9700287A (es) Composicion de oxitetraciclina de accion prolongada.
ATE274337T1 (de) Polyelektrolytzement
EA200001165A1 (ru) Производные тетрагидрохинолина в качестве антагонистов глицина
ES466851A1 (es) Procedimiento para la preparacion de 2-bromo-6-fluor-n-2- imidazolidinilidenbenzamina.
GB2324528B (en) Cytostatic hydroxamic acid derivatives
ES2048666B1 (es) Un preparado enzimatico estable a base de celulosas y proteasas.
ES2033242T3 (es) Compuestos organicos y su uso farmaceutico.
EA200001107A1 (ru) ПРОИЗВОДНЫЕ ОКТАГИДРО-6,10-ДИОКСО-6H-ПИРИДАЗИНО [1,2-a] [1,2] ДИАЗЕПИН-1-КАРБОНОВОЙ КИСЛОТЫ, СПОСОБ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ ДЛЯ ПОЛУЧЕНИЯ ТЕРАПЕВТИЧЕСКИ АКТИВНЫХ СОЕДИНЕНИЙ
KR880002868A (ko) 피리도 피리미딘 디온
MX169229B (es) Procedimiento para la fabricacion de un lapicero de pegamento perfeccionado
JPS6413083A (en) Streptonigrin derivative and medicinal composition
ES2061935T3 (es) 5-fluorometil-1,2,4-triazolo(1,5-a) pirimidina-2-sulfonamidas, procedimiento para preparacion y composiciones para su uso como herbicidas.